|
|
|
|
|
Presentations and Events: 200512 December, 2005: TopoTarget and CuraGen poster presentation at the American Society of Hematology (ASH) Annual Meeting, “Activity of the Histone Deacetylase (HDAC) Inhibitor PXD101 in Preclinical Studies and in a Phase I Study in Patients with Advanced Hematological Tumors.”
English version only.
12 December, 2005: University of Pittsburgh poster presentation at the American Society of Hematology (ASH) Annual Meeting, “Combination of Proteasome Inhibitor PS-341 (Velcade®) with the Histone Deacetylase Inhibitor (HDAC) PXD101 Shows Superior Anti-Myeloma Activity and Inhibits Osteoclastogenesis.”
English version only.
17 November, 2005: Q3 presentation including 9 months’ results, financial status, and the developmental achievements in the 3rd quarter followed by an update on the clinical development programmes and news flow expectations
Danish
22 September, 2005: TopoTarget participated in a Nordic Investment Meeting at the Copenhagen Stock Exchange where CEO Peter Buhl Jensen and COO Tim Corcoran presented the company at 12:25pm-12:55pm. Click on the following to link to a live webcast of the event.
http://www.stockwise.tv/ws3/MGPplayers/default.asp?id=426TopoTarget - offentliggørelse af prospekt (webcast in Danish)Conference Call at 1 PM - Interim report Six months ended 30 June 2005 (webcast in Danish)
|
|
|
About Us
Cancer